Form 4: Jazz Pharmaceuticals Director Seamus Mulligan Increases Stake in Company

Director Seamus Mulligan reports purchasing Jazz Pharmaceuticals shares through Nerano Pharma Limited in multiple transactions.

Summary

• Seamus Mulligan, a director of Jazz Pharmaceuticals plc, has reported the acquisition of additional ordinary shares.
• The transactions occurred on May 9, 2025, and May 12, 2025.
• The shares were purchased indirectly through Nerano Pharma Limited, an entity owned and controlled by Mulligan and his immediate family.
• On May 9, 2025, 80,684 shares were purchased at a weighted average price of $98.1046, 19,216 shares were purchased at a weighted average price of $98.9112 and 100 shares were purchased at $99.71.
• On May 12, 2025, 1,621 shares were purchased at a weighted average price of $102.9991.
• Following these transactions, Mulligan indirectly holds 101,621 shares through Nerano Pharma Limited and directly holds 1,176,106 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's purchase of shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's increased investment in the company may signal confidence in its future prospects.

Industry Context

Director share purchases are common and are often seen as a positive sign, indicating the director's belief in the company's future performance. However, they can also be influenced by factors specific to the individual's financial situation.

Related Party Transactions

• The shares were purchased indirectly through Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.

Stakeholder Impact

• The increased stake by a director could be viewed positively by shareholders.

Key Dates

Keywords

Jazz Pharmaceuticals, Seamus Mulligan, Nerano Pharma Limited, share purchase, director, JAZZ, beneficial ownership